cyclin C Inhibitors

H-8 • 2HCl acts as a potent modulator of cyclin C, influencing its interaction with cyclin-dependent kinases. The compound exhibits unique electrostatic interactions that stabilize the cyclin C-CDK complex, enhancing its regulatory role in cell cycle control. Its distinct structural features facilitate selective binding, altering the conformational dynamics of the kinase, which can lead to significant changes in downstream signaling pathways and cellular responses.

Flavopiridol is a potent inhibitor of cyclin-dependent kinases (CDKs), including CDK3/cyclin C. By targeting CDK activity, flavopiridol disrupts the cell cycle progression and inhibits the phosphorylation events regulated by cyclin C, leading to the suppression of downstream cellular processes dependent on cyclin C-associated kinase activity.

Purvalanol A is a selective CDK inhibitor that affects cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase 3 (CDK3), among others. Its inhibition of CDK3/cyclin C complexes disrupts the cell cycle, impeding the normal progression of cells through different phases. This interference with cyclin C-associated kinase activity is a key aspect of purvalanol A's mechanism of action.

Roscovitine, also known as seliciclib, is a cyclin-dependent kinase inhibitor that targets CDK2 and CDK3. By inhibiting these kinases, particularly CDK3/cyclin C complexes, roscovitine disrupts the cell cycle and influences the phosphorylation events regulated by cyclin C, leading to a blockade of cell cycle progression and interfering with cyclin C-associated functions.

Indirubin is a natural compound that inhibits cyclin-dependent kinases, including CDK2 and CDK3. Through its action on CDK3/cyclin C complexes, indirubin disrupts cell cycle progression and interferes with the phosphorylation events regulated by cyclin C, contributing to the inhibition of downstream cellular processes dependent on cyclin C-associated kinase activity.

Kenpaullone is a CDK inhibitor that targets multiple cyclin-dependent kinases, including CDK2 and CDK3. Its impact on CDK3/cyclin C complexes disrupts the cell cycle, inhibiting the normal progression of cells through different phases. By interfering with cyclin C-associated kinase activity, kenpaullone exerts its inhibitory effects on downstream cellular processes regulated by cyclin C.

Dinaciclib is a potent inhibitor of CDKs, including CDK2 and CDK3. Its action on CDK3/cyclin C complexes disrupts the cell cycle, hindering the normal progression of cells. By interfering with cyclin C-associated kinase activity, dinaciclib influences the phosphorylation events regulated by cyclin C, leading to the inhibition of downstream cellular processes dependent on cyclin C-associated functions.

SNS-032 is a selective inhibitor of CDKs, targeting CDK2 and CDK3. Its inhibition of CDK3/cyclin C complexes disrupts the cell cycle and interferes with the phosphorylation events regulated by cyclin C, contributing to the suppression of downstream cellular processes dependent on cyclin C-associated kinase activity. SNS-032's mechanism of action centers on its interference with cyclin C-associated functions.

PHA-793887 is a selective inhibitor of CDKs, including CDK2 and CDK3. By targeting CDK3/cyclin C complexes, PHA-793887 disrupts the cell cycle, inhibiting the normal progression of cells. Its interference with cyclin C-associated kinase activity influences the phosphorylation events regulated by cyclin C, leading to the suppression of downstream cellular processes dependent on cyclin C-associated functions.

AZD5438 is a CDK inhibitor that affects various cyclin-dependent kinases, including CDK2 and CDK3. Its inhibition of CDK3/cyclin C complexes disrupts the cell cycle, impeding the normal progression of cells through different phases. By interfering with cyclin C-associated kinase activity, AZD5438 influences the phosphorylation events regulated by cyclin C, contributing to the inhibition of downstream cellular processes.